Exchange: NYSEArca·Updated 04:10 PM EDT
PBE logo

PBEInvesco Dynamic Biotechnology & Genome ETF

$89.65
$0.1165
(0.13%)
Today
Closed $89.65
$0.00
(0.00%)
After Hours
Vol5,170.00
52W High$90.33
52W Low$63.92
News
all
press releases
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Smart Beta ETF report for PBE
Zacks
News Placeholder
More News
News Placeholder
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
Zacks
News Placeholder
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Smart Beta ETF report for PBE
Zacks
News Placeholder
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
Zacks
News Placeholder
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Smart Beta ETF report for PBE
Zacks
News Placeholder
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
Zacks
News Placeholder
Why Did MNKD Stock Jump Over 7% In Pre-Market Today?
The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.
Stocktwits
News Placeholder
Inside the Recent Strength in Biotech ETFs
Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.
Zacks
News Placeholder
2 ETFs to Watch for Outsized Volume on Biotechnology Stocks
Biotech ETFs PBE and FBT saw trading volumes soar to over four times their averages, signaling rising interest amid a down day for major indexes.
Zacks
News Placeholder
MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters
The company has now also submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged 4-17 years.
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.